Oral biologic shows promise in RA

A highly anticipated RA treatment has demonstrated its efficacy in patients for whom conventional DMARDs either did not work or weren’t tolerated.

Baricitinib is a selective JAK1 and 2 inhibitor which is now being tested in four global phase 3 trials. The current study randomised nearly 700 patients with moderate to severe RA who were refractory to conventional therapy to once daily doses of either baricitinib 2mg, 4mg, or placebo.